Email
TextLatest News on Clinical Trials
Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with Pfizer’s CDK4/6 Inhibitor Palbociclib
Calithera Biosciences, Inc. (CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced treatment of the first patient in a Phase 1/2...
Monopar Therapeutics and the Spanish Sarcoma Group (GEIS) Team Up on Phase 2 Sarcoma Trial With Monopar’s Novel Camsirubicin
Trial Designed to Test Camsirubicin Against Doxorubicin as First-Line Therapy Monopar Therapeutics Inc., an oncology-focused biopharmaceutical company, and the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS) today announced that they have...
AskBio’s Perspective on Pfizer’s 1b Clinical Trial Results on Duchenne MD Gene Therapy
On the forefront of the gene therapy industry, AskBio celebrates the accomplishments of all companies for their work in finding curative therapies for life-threatening diseases. Pfizer reported results from a Phase 1b clinical trial of PF-06939926, its investigational...
Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087
Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that the U.S. Food and Drug Administration (FDA) has...
Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery
Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing blood-derived stem cell therapies for unmet medical conditions, is pleased to announce that it’s abstract was accepted at the...
TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer
Phase 1 Data Published in ASCO Proceedings Determined the Recommended Phase 2 Dose Additional Cohort of Patients with a Specific Androgen Receptor Point Mutation Added to Ongoing Phase 2 Study Phase 2 Data Expected in 2nd half 2020; Potential for $45 Million Opt-in...
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the dosing of the first patient in its...
Apexian Pharmaceuticals’ Clinical Candidate, APX3330, to Be Studied in Diabetic Models of Preleukemic Cells With Specific Mutations to Leukemia
Apexan Pharmaceuticals, Inc. is pleased to announce that The National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health has awarded a $2.3 million grant to Dr. Reuben Kapur and Dr. Mark R. Kelley, investigators in the Wells Center for...
Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the European Commission (EC) has granted orphan drug designation (ODD) to...
New study showing drug prolongs life for patients with ovarian cancer
Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives in a meaningful way. However, a new research study shows tremendous promise for a drug called...
Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)
FDA agreed that the ongoing single-arm Phase 2 innovaTIL-04 study may be sufficient to support registration of LN-145 in advanced cervical cancer Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies...
Asklepion Pharmaceuticals concludes enrollment of Phase III trial: L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects
Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of novel therapeutics for rare pediatric diseases, today announced the completion of enrollment of its Phase III double-blind, randomized, placebo...
vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
I vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes. In a post hoc...
Bioinvent Receives Ind Approval For Phase I/iia Trial of Anti-fcγriib Antibody
BioInvent International AB (BINV) today announces it has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with an Investigational New Drug (IND) application for a Phase I/IIa clinical trial of an immune-modulatory anti-FcγRllB...
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that the first patient has been...
Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open label Phase 1 clinical trial...
Pfizer Completes Acquisition of Therachon: Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470...
Genkyotex’s GKT831 Prevents Multiple Complications of Portal Hypertension in Preclinical Model
Data Supports Therapeutic Role of GKT831 in Advanced Liver Fibrosis Results published in Clinics and Research in Hepatology and Gastroenterology Phase 3 trial being planned in primary biliary cholangitis ARCHAMPS, France, July 01, 2019 (GLOBE NEWSWIRE) -- Genkyotex...
Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis
Data show crisaborole ointment, 2%, a steroid-free topical treatment, was well-tolerated over 4-week treatment period Safety profile consistent with previous clinical trial experience Pfizer Inc. (PFE) today announced top-line results from a Phase 4 study (CrisADe...
Vedanta Biosciences Announces First Patient Enrolled in VE416 Phase 1b/2 Food Allergy Clinical Study
First clinical study of a rationally-defined bacterial consortium (VE416) for treating food allergy, will initially be studied in patients with history of peanut allergy Antigen-agnostic approach could potentially be used to address multiple food allergies Vedanta...